Specific Biomarkers Involved in Sarcoidosis Diagnosis and Prognosis
Elena Matei1, Viorica Pîslan Zamfir2,3, Victoria-Cristina Șuța4,5
1Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology, "Ovidius" University of Constanta, 145 Tomis Boulevard, 900591 Constanta, Romania.
International Journal of Molecular Sciences
|July 28, 2026
Summary
This study identifies specific CD biomarkers, like CD8a+CD45+ and CD4+ T-helper cells, as accurate diagnostic and prognostic indicators for sarcoidosis. These biomarkers help predict disease progression and treatment response in patients.
Area of Science:
- Immunology
- Biomarker Discovery
- Flow Cytometry
Background:
- Sarcoidosis is an inflammatory disease characterized by granulomatous inflammation.
- Identifying reliable biomarkers is crucial for diagnosis and prognosis.
Purpose of the Study:
- To identify and validate CD biomarkers for sarcoidosis diagnosis and prognosis.
- To analyze inflammatory responses in sarcoidosis patients using flow cytometry.
Main Methods:
- Flow cytometry was used to analyze inflammatory cell populations in sarcoidosis patients.
- Specific cell surface markers including CD8a+CD45+, CD4+ T-helper cells, and CD3+CD56+CD16+ (iNKT) were quantified.
Main Results:
- CD8a+CD45+ expression (M1 macrophage phenotype) accurately diagnoses active sarcoidosis and predicts progression.
- Activated CD4+ T-helper cells are accurate diagnostic biomarkers.
- CD3+CD56+CD16+ (iNKT) predicts disease progression and correlates positively with treatment.
Conclusions:
- CD biomarker analysis provides accurate diagnostic and prognostic models for sarcoidosis.
- These biomarkers are valuable tools for understanding disease progression and inflammatory phenotypes.
